Axogen, Inc. (AXGN): Price and Financial Metrics

Axogen, Inc. (AXGN): $20.56

0.87 (+4.42%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AXGN ranks best; there it ranks ahead of 86.3% of US stocks.
  • The strongest trend for AXGN is in Stability, which has been heading up over the past 31 weeks.
  • AXGN ranks lowest in Stability; there it ranks in the 41st percentile.

AXGN Stock Summary

  • AXGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 139.12 -- higher than 79.83% of US-listed equities with positive expected earnings growth.
  • AXGN's went public 31.22 years ago, making it older than 84.21% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 1,810.96%, Axogen Inc's debt growth rate surpasses 98.97% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Axogen Inc are XXII, ALKS, REFR, CUTR, and FLNT.
  • Visit AXGN's SEC page to see the company's official filings. To visit the company's web site, go to

AXGN Price Target

For more insight on analysts targets of AXGN, see our AXGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.17 Average Broker Recommendation 1.43 (Moderate Buy)

AXGN Stock Price Chart Interactive Chart >

Price chart for AXGN

AXGN Price/Volume Stats

Current price $20.56 52-week high $23.94
Prev. close $19.69 52-week low $8.77
Day low $19.64 Volume 132,800
Day high $20.57 Avg. volume 243,979
50-day MA $19.92 Dividend yield N/A
200-day MA $17.17 Market Cap 843.02M

Axogen, Inc. (AXGN) Company Bio

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.

AXGN Latest News Stream

Event/Time News Detail
Loading, please wait...

AXGN Latest Social Stream

Loading social stream, please wait...

View Full AXGN Social Stream

Latest AXGN News From Around the Web

Below are the latest news stories about Axogen Inc that investors may wish to consider to help them evaluate AXGN as an investment opportunity.

AxoGen (AXGN) Investor Presentation - Slideshow

The following slide deck was published by AxoGen, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | May 24, 2021

AxoGen reiterates 2021 guidance despite decision to suspend market availability of Avive

AxoGen (AXGN) lost ~3.6% in the post-market after announcing its decision to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, subject to ongoing discussions with the FDA on its regulatory classification.The decision not to market Avive, a product sold by the company since 2016, was not “based on any...

Seeking Alpha | May 18, 2021

Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA

Axogen Inc (NASDAQ: AXGN ) has announced to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, pending ongoing discussions with the FDA regarding the regulatory classification of Avive, according to SEC filing . This announcement applies only to Avive, representing approximately 5% of Company revenue and has no impact on any other Axogen product, including the Avance Nerve Graft. In a written agreement with the FDA, Axogen can continue legally market Avance as … Full story available on

Benzinga | May 18, 2021

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2021

Axogen, Inc. Reports 2021 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2021. First Quarter 2021 Financial Results and Business Highlights Net revenue was $31.0 million during the quarter, a 28% increase compared to first quarter 2020 revenue of $24.3 million.Gross margin was 83.3% for the quarter, compared to 80.1% in the first quarter of 2020.Net loss for the quarter was $6.7 million, or $0.16 per share, compared to a net loss of $8.2 million, or $0.21 per share, in the first quarter of 2020.Adjusted net loss was $3.1 million for the quarter, or $0.08 per share, compa...

Yahoo | May 5, 2021

Read More 'AXGN' Stories Here

AXGN Price Returns

1-mo -4.24%
3-mo 1.43%
6-mo 24.61%
1-year 123.48%
3-year -59.00%
5-year 271.79%
YTD 14.86%
2020 0.06%
2019 -12.43%
2018 -27.81%
2017 214.44%
2016 80.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9723 seconds.